In a report released today, Charles Pitman CFA from Barclays maintained a Buy rating on Lonza Group Ltd (LONN – Research Report), with a price ...

With an aim to enhance its service offering for particle technologies and drug product development and manufacture, Lonza has joined CMAC, an international research hub with a unique configuration of ...

Lonza will now gain access to CMAC’s network, which advances CMC technologies and implements digitalization strategies.

SWX:LONN Earnings and Revenue History April 11th 2025 How Do Unusual Items Influence Profit? To properly understand Lonza Group's profit results, we need to consider the CHF284m e ...

In a report released today, Patrick Rafaisz from UBS maintained a Buy rating on Lonza Group Ltd (LONN – Research Report), with a price target ...

Lonza Group (LZAGY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Lonza Group Ag (LZAGY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one ...

Drug manufacturers are rushing to reshape their supply chains amid President Donald Trump’s escalating tariff threats, leading to a potential windfall for contractors that make medications in the US.

MUNICH, Germany & BASEL, Switzerland I April 07, 2025 I Ethris, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, and Lonza, one of the world’s largest ...

These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved.

These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors ...